What is Medable?
Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Its core mission is to revolutionize clinical trial execution by enabling the seamless integration of patient-generated data. This capability is crucial for driving advancements in precision medicine and predictive analytics, ultimately aiming to expedite the discovery and delivery of life-saving treatments. The company's platform addresses critical bottlenecks in traditional clinical research, fostering a more efficient and patient-centric approach to drug development.
How much funding has Medable raised?
Medable has raised a total of $518.8M across 6 funding rounds:
Series A
$3.6M
Series B
$16.2M
Debt
$1M
Other Financing Round
$25M
Series C
$169M
Series D
$304M
Series A (2015): $3.6M, investors not publicly disclosed
Series B (2018): $16.2M, investors not publicly disclosed
Debt (2020): $1M supported by PPP
Other Financing Round (2020): $25M featuring GSR Ventures and PPD, Inc
Series C (2021): $169M backed by Sapphire Ventures LLC, Obvious Ventures, Streamline Ventures, GSR Ventures, and PPD Group Inc
Series D (2021): $304M with participation from Blackstone Accelerates Growth, Tiger Global Management, WTI - Western Telematic, Sapphire Ventures, and GSR Ventures
Key Investors in Medable
Blackstone Accelerates Growth
Blackstone Accelerates Growth (BxG) is an investment entity focused on fostering economic development through entrepreneurship and company growth, operating as part of the Blackstone Charitable Foundation.
Tiger Global Management
Tiger Global Management is an investment firm that deploys capital across both public and private markets, founded in 2001 and headquartered in New York City.
Sapphire Ventures
Sapphire Ventures is a venture capital firm specializing in investments and services for technology companies, with its base in Palo Alto, California.
What's next for Medable?
With substantial enterprise-level backing and a recent strategic investment, Medable is well-positioned for accelerated growth and market expansion. The company's focus on leveraging technology to enhance clinical trial efficiency and data integrity suggests a strategic trajectory towards becoming a dominant force in the digital health and clinical research sectors. Future developments are likely to involve further platform enhancements, broader adoption by pharmaceutical and biotech companies, and continued innovation in areas such as decentralized clinical trials and real-world evidence generation. The company's ability to attract significant capital indicates strong investor confidence in its long-term vision and its capacity to transform the clinical research landscape.
See full Medable company page
